We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

III:LSE3i Group plc Analysis

Data as of 2026-06-14 - not real-time

£2,309.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

III is trading at roughly £23.09 per share, well below its DCF‑derived fair value of £43.71, implying a potential upside of over 45 %. The stock’s trailing P/E of 4.28 is dramatically lower than the asset‑management industry average of 16.83, underscoring a deep valuation discount. A dividend yield of 3.66 % combined with a modest payout ratio of 14.7 % suggests the dividend is comfortably sustainable. Recent results show a 22 % total return for FY‑2026 and NAV per share up 19 % to £30.30, driven by strong performance in the Action retailer and private‑equity portfolios. On the technical side, the 20‑day SMA (2,218) sits above price, while the 50‑day (2,466) and 200‑day (3,260) SMAs remain well above, indicating a long‑term bearish backdrop. However, the MACD histogram is positive and the MACD signal is bullish, hinting at short‑term momentum improvement near the current resistance of 2,364.
Volatility remains high at 58 % over the past 30 days and the max drawdown exceeds 53 %, reflecting sizable price swings. The beta of 0.90 points to lower systematic risk than the market, while decreasing volume may limit short‑term liquidity. The company’s debt‑to‑equity ratio of 4.08 is elevated, but strong operating cash flow and a free cash flow generation of £3.39 bn support balance‑sheet resilience. The sector’s regulatory environment and broad geographic exposure introduce moderate regulatory and geographic risks. Overall, the combination of a sizable valuation gap, solid earnings, and a sustainable dividend outweighs the technical bearish trend in the medium‑term view. Investors should therefore consider a measured entry, capitalising on upside potential while monitoring technical levels.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price hovering near resistance at 2,364
  • decreasing trading volume
  • bullish MACD signal despite long‑term bearish SMAs

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • valuation upside >45% versus DCF fair value
  • sustainable dividend yield of 3.66% with low payout
  • strong FY‑2026 performance delivering 22% total return

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • significant valuation gap and low P/E relative to peers
  • diversified global portfolio reducing concentration risk
  • low beta and robust cash‑flow generation supporting stability

Key Metrics & Analysis

Financial Health

Revenue Growth-33.40%
Profit Margin94.84%
P/E Ratio4.3
ROE19.08%
ROA11.66%
Debt/Equity4.08
P/B Ratio0.8
Op. Cash Flow£998.0M
Free Cash Flow£3.4B
Industry P/E16.8

Technical Analysis

TrendBearish
RSI50.3
Support£2,043.00
Resistance£2,364.00
MA 20£2,218.10
MA 50£2,465.74
MA 200£3,259.66
MACDBullish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

Fair Value£4,371.45
Target Price£3,362.20
Upside/Downside45.61%
GradeUndervalued
TypeBlend
Dividend Yield3.66%

Risk Assessment

Beta0.90
Volatility58.04%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.